By Toni Clarke WASHINGTON (Reuters) - AstraZeneca Plc's diabetes drug Onglyza and Takeda Pharmaceutical Co.'s rival product Nesina should carry information about the risk of heart failure, an advisory committee to the U.S. Food and Drug Administration said on Tuesday. Heart failure is a condition in which the heart cannot pump enough blood to meet the body's needs. It can be caused by coronary artery disease, high blood pressure, diabetes or obesity, according to the Mayo Clinic. The panel reviewed safety data on AstraZeneca's Onglyza and Takeda's Nesina.
via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment